Transient autoimmune hyperthyroidism following the withdrawal of Natalizumab in patients with multiple sclerosis.
Multiple Sclerosis Unit, Department of Neurology, Hospital General Universitario de Valencia, Valencia, Spain, marida.c@hotmail.com.
María
M
Carcelén-Gadea
Juan Carlos
JC
Ferrer-Garcia
Angeles
A
Cervelló Donderis
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006111:Graves Disease / Q000150:complications / Q000175:diagnosis*; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D000069442:Natalizumab; D055815:Young Adult
D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab